Status:
UNKNOWN
CURATE.AI COR-Tx Trial for Post Brain Radiotherapy Patients
Lead Sponsor:
National University Hospital, Singapore
Collaborating Sponsors:
National University of Singapore
The N.1 Institute for Health (N.1)
Conditions:
Cognitive Decline
Eligibility:
All Genders
21-99 years
Phase:
NA
Brief Summary
Cognitive deficit is common in patients who have undergone whole brain or partial brain radiotherapy. To counteract intellectual deterioration, the conventional strategies includes drug- based treatme...
Detailed Description
Brain radiotherapy causes downstream cognitive deficits. Drug-based cognitive decline treatments show little improvement and side effects may reduce patient compliance. Regimens are usually administer...
Eligibility Criteria
Inclusion
- Age \>21 years.
- ECOG performance status 0 to 2.
- Patients with a neoplastic condition (benign or malignant) involving the brain or skull requiring radiotherapy (with or without chemotherapy).
- Patients with a life expectancy of at least 6 months.
Exclusion
- Pregnant or breastfeeding women.
- Patients undergoing stereotactic radiosurgery (single fraction).
- Patients who are undergoing re-irradiation to the same area of the brain.
- Patients physically incapable of using computer tablet (either due to vision loss or dominant hand weakness)
- Patients who cannot understand spoken English language.
- Patients who are unable to give informed consent.
Key Trial Info
Start Date :
June 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04848935
Start Date
June 14 2021
End Date
July 1 2022
Last Update
November 12 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore
2
The N.1 Institute for Health (N.1), NUS
Singapore, Singapore